These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22068987)

  • 1. Pegloticase and chronic gout.
    Ea HK; Chales G; Lioté F
    JAMA; 2011 Nov; 306(18):1979; author reply 1979-80. PubMed ID: 22068987
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
    Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
    JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegloticase: a novel agent for treatment-refractory gout.
    Shannon JA; Cole SW
    Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegloticase (krystexxa) for treatment of refractory gout.
    Med Lett Drugs Ther; 2011 Feb; 53(1357):9-10. PubMed ID: 21304442
    [No Abstract]   [Full Text] [Related]  

  • 5. The Needle or Knife: Pegloticase for Refractory Crippling Gout in a Nonagenarian.
    Choi N; Eickhoff J; Keith M
    J Clin Rheumatol; 2017 Sep; 23(6):343. PubMed ID: 28816765
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
    Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
    Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout.
    Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD
    J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegloticase and the patient with treatment-failure gout.
    Dave AJ; Kelly VM; Krishnan E
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
    Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
    Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo.
    Hershfield MS; Roberts LJ; Ganson NJ; Kelly SJ; Santisteban I; Scarlett E; Jaggers D; Sundy JS
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14351-6. PubMed ID: 20660758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegloticase for treating refractory chronic gout.
    George RL; Sundy JS
    Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of chronic refractory tophaceous gout with erosions with pegloticase.
    Yeter KC; Ortiz EC; Arkfeld DG
    Int J Rheum Dis; 2013 Jun; 16(3):369-70. PubMed ID: 23981765
    [No Abstract]   [Full Text] [Related]  

  • 13. Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Khanna PP; Khanna D; Cutter G; Foster J; Melnick J; Jaafar S; Biggers S; Rahman AKMF; Kuo HC; Feese M; Kivitz A; King C; Shergy W; Kent J; Peloso PM; Danila MI; Saag KG
    Arthritis Rheumatol; 2021 Aug; 73(8):1523-1532. PubMed ID: 33750034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout.
    Biggers K; Scheinfeld N
    Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.
    Johnson RJ; Choi HK; Yeo AE; Lipsky PE
    Hypertension; 2019 Jul; 74(1):95-101. PubMed ID: 31079535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
    Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
    J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?
    Fini MA; Stenmark KR
    Eur J Intern Med; 2019 Nov; 69():e11-e12. PubMed ID: 31471165
    [No Abstract]   [Full Text] [Related]  

  • 18. Alternative treatment for chronic gout could relieve pain for thousands. The recently approved intravenous drug, pegloticase, may work when other treatments don't.
    Duke Med Health News; 2013 Jan; 19(1):3. PubMed ID: 23762971
    [No Abstract]   [Full Text] [Related]  

  • 19. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients.
    Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS
    Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-ing down (and preventing?) the cause of pegloticase failure.
    Abeles AM
    Arthritis Res Ther; 2014 May; 16(3):112. PubMed ID: 25142440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.